Archon Biosciences develops AI-driven Antibody Cages to enhance antibody treatments by improving target engagement and biodistribution.

Parse Biosciences is a company that develops and commercializes scalable single-cell sequencing technologies for use in over 1,000 labs globally, aiming to expand its product range and market presence with its recent $50 million funding.